Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Phytoscience
Published in: Clinical Phytoscience 1/2015

Open Access 01-12-2015 | Original contribution

Safety of Canephron® N for the treatment of urinary tract infections in the first trimester of pregnancy

Author: Volodymir Medved

Published in: Clinical Phytoscience | Issue 1/2015

Login to get access

Abstract

Background

Urinary tract infections (UTIs) are among the most commonly occurring bacterial infections, particularly in pregnant women. Canephron® N (Bionorica, Germany) is a phytotherapeutic medicinal product that has pleiotrophic effects on the urinary system, including diuretic, spasmolytic, anti-inflammatory, antimicrobial and nephroprotective effects. The purpose of this retrospective study was to assess the safety of Canephron® N when used in the first trimester of pregnancy for the treatment of UTIs.

Methods

This was a retrospective, multi-center study that evaluated the effects of Canephron® N in 384 women who had used the herbal drug during the first trimester of pregnancy (between 2004 and 2009), and whose pregnancies ended in live births. The endpoints assessed in this study were the presence of congenital defects in the newborn.

Results

There were no significant differences in the incidence of congenital malformations in newborns whose mothers had taken Canephron® N in the first trimester of pregnancy, compared to the national statistical data for the Kiev population during the same period. The majority of newborns (>65 %) whose mothers had received Canephron® N during the first trimester of pregnancy had Apgar scores of 8 or above, indicating an excellent safety status.

Conclusions

The results from our study indicate that the use of Canephron® N during the first trimester of pregnancy was not associated with any teratogenic, embryotoxic or fetotoxic effects on the fetus.
Literature
1.
Matuszkiewicz-Rowinska J, Malyszko J, Wieliczko M. Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. Arch Med Sci. 2015;11:67–77.PubMedCentralCrossRefPubMed
2.
3.
Ronald AR, Pattullo AL. The natural history of urinary infection in adults. Med Clin North Am. 1991;75:299–312.PubMed
4.
McKenna DS, Matson S, Northern I. Maternal group B streptococcal (GBS) genital tract colonization at term in women who have asymptomatic GBS bacteriuria. Infect Dis Obstet Gynecol. 2003;11:203–7.PubMedCentralCrossRefPubMed
5.
6.
Rizvi M, Khan F, Shukla I, Malik A. Shaheen. Rising prevalence of antimicrobial resistance in urinary tract infections during pregnancy: necessity for exploring newer treatment options. J Lab Physicians. 2011;3:98–103.PubMedCentralCrossRefPubMed
7.
Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006;107:1120–38.CrossRefPubMed
8.
Pacifici GM. Placental transfer of antibiotics administered to the mother: a review. Int J Clin Pharmacol Ther. 2006;44:57–63.CrossRefPubMed
9.
Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf. 2014;13:1569–81.CrossRefPubMed
10.
Nicolle LE. Short-term therapy for urinary tract infection: success and failure. Int J Antimicrob Agents. 2008;31 Suppl 1:S40–5.CrossRefPubMed
11.
Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med. 2014;12:121–7.PubMedCentralCrossRefPubMed
12.
Martinez de TB. Antibiotic use and misuse during pregnancy and delivery: benefits and risks. Int J Environ Res Public Health. 2014;11:7993–8009.CrossRef
13.
Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14:742–50.CrossRefPubMed
14.
Haloui M, Louedec L, Michel JB, Lyoussi B. Experimental diuretic effects of Rosmarinus officinalis and Centaurium erythraea. J Ethnopharmacol. 2000;71:465–72.CrossRefPubMed
15.
Yarnell E. Botanical medicines or the urinary tract. World J Urol. 2002;20:285–95.PubMed
16.
Yamahara J, Konoshima I, Sawada I, Fujimura H. Biologically active principles of crude drugs: pharmacological actions of Swertia japonica extracts, swertiamarine and gentianine. Yakugaku Zasshi. 1978;98:1446–51.PubMed
17.
Abdul-Ghani AS, El-Lati SG, Sacaan A. Anticonvulsant effects of some Arab medicinal plants. Int J Crude Drug Res. 1987;25:39–43.
18.
Gracza L, Koch H. Lo¨ffler E. Isolierung von rosmarin saure aus symphytum officinale und ihre antiinflammatorische wirksamkeit in einem in-vitro.Modell. Arch Pharm. 1985;318:1090–5.CrossRef
19.
Rampart M, Beetjens JR, Bult H. Complementdependent stimulation of prostacyclin biosynthesis; inhibition by rosmarinic acid. Biochem Pharmacol. 1986;35:1397–400.CrossRefPubMed
20.
Valentao P, Fernandes E, Carvalho F. Hydroxyl radical and hypochlorous acid scavenging activity of small centaury (Centaurium erythraea) infusion. A comparative study with green tea (Camellia sinensis). Phytomedicine. 2003;10:517–22.CrossRefPubMed
21.
European Scientific Cooperative on Phytotherapy. Centaurii herba (Centaury herb). In: ESCOP Monographs. 2nd ed. Stuttgart, Germany, and New York: Thieme-Verlag; 2003. p. 70–3.
22.
European Scientific Cooperative on Phytotherapy. Rosmarini folium (Rosemary leaves). In: ESCOP Monographs. 2nd ed. Stuttgart, Germany, and New York: Thieme-Verlag; 2003. p. 429–36.
23.
Kumarasamy Y, Nahar L, Cox PJ. Bioactivity of secoiridoid glycosides from Centaurium erythraea. Phytomedicine. 2003;10:344–7.CrossRefPubMed
24.
Kumarasamy Y, Nahar L, Sarker SD. Bioactivity of gentiopicroside from the aerial parts of Centaurium erythraea. Fitoterapia. 2003;74:151–4.CrossRefPubMed
25.
Sterner W, Heisler E, Popp HO, Fischer H. Studien uber die canephron-wirkung bei chronischen nierenerkrankungen. Phys Med Rehabil. 1973;14:239–58.
26.
Gaybullaev AA, Kariev SS. Effects of the herbal combination Canephron® N on urinary risk factors of idiopathic calcium urolithiasis in an open study. Z Phytother. 2013;34:16–20.CrossRef
27.
Naber KG. Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol. 2013;5:39–46.PubMedCentralPubMed
28.
Bai J, Wong FW, Bauman A, Mohsin M. Parity and pregnancy outcomes. Am J Obstet Gynecol. 2002;186:274–8.CrossRefPubMed
29.
30.
Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med. 2001;344:467–71.CrossRefPubMed
31.
Gilbert NM, O’Brien VP, Hultgren S, Macones G, Lewis WG, Lewis AL. Urinary tract infection as a preventable cause of pregnancy complications: opportunities, challenges, and a global call to action. Glob Adv Health Med. 2013;2:59–69.PubMedCentralCrossRefPubMed
32.
Schnarr J, Smaill F. Asymptomatic bacteriuria and symptomatic urinary tract infections in pregnancy. Eur J Clin Invest. 2008;38 Suppl 2:50–7.CrossRefPubMed
33.
Bolton M, Horvath Jr DJ, Li B, Cortado H, Newsom D, White P, et al. Intrauterine growth restriction is a direct consequence of localized maternal uropathogenic Escherichia coli cystitis. PLoS One. 2012;7:e33897.PubMedCentralCrossRefPubMed
34.
Gilbert-Barness E. Teratogenic causes of malformations. Ann Clin Lab Sci. 2010;40:99–114.PubMed
35.
Medved VI, Bykova LM, Danylkiv OE, Shkabarovskaya EN. Pathogenic justification and efficiency of improved therapy of pyelonephritis in pregnant women with diabetes mellitus. Womens Reprod Health. 2015;2:35–8.
36.
Ordzhonikidze NV, Yemelyanova AI, Petrova SB. Complication prevention and treatment in pregnants and puerperants with urinary tract diseases. Obstet Gynecol. 2009;6:41–5.
37.
Potapo VA, Demchenko TV, Medvedev MV. Pathogenetic therapy of gestational toxicosis in patients with renal disease. Health Ukraine. 2004;5:1–2.
38.
Medved VI, Islamova EV. To the question on safety of the preparation Canephron® N in the obstetric practice. Med Aspects Womens Health. 2009;4:32–5.
39.
Repina MA, Kolchina VA, Kuzmina-Krutetskaya SR, Stambulova OA, Golubenko NA. Phytopreparations in the treatment of renal diseases in pregnant women and long-term safety results in born children. J Obstet Womens Dis. 2006;1:50–6.
Metadata
Title
Safety of Canephron® N for the treatment of urinary tract infections in the first trimester of pregnancy
Author
Volodymir Medved
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Clinical Phytoscience / Issue 1/2015
Electronic ISSN: 2199-1197
DOI
https://doi.org/10.1186/s40816-015-0012-1

Other articles of this Issue 1/2015

Clinical Phytoscience 1/2015 Go to the issue

Original Contribution

An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the management of uncomplicated urinary tract infections (uUTIs)

Original contribution

Hepatoprotective effect of oral application of a silymarin extract in carbon tetrachloride-induced hepatotoxicity in rats

Original contribution

Phytotherapy in acute bronchitis: what is the evidence?

Review

Black cohosh (Cimicifuga racemosa) is a non-estrogenic alternative to hormone replacement therapy

Review

Cruciferous vegetables: prototypic anti-inflammatory food components

Original contribution

Sinupret® oral drops protect against respiratory epithelium atrophy in experimental acute rhinitis